ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

  1. Tripathy, D.
  2. Tolaney, S.M.
  3. Seidman, A.D.
  4. Anders, C.K.
  5. Ibrahim, N.
  6. Rugo, H.S.
  7. Twelves, C.
  8. Dieras, V.
  9. Müller, V.
  10. Tagliaferri, M.
  11. Hannah, A.L.
  12. Cortés, J.
Zeitschrift:
Future Oncology

ISSN: 1744-8301,  1479-6694

Datum der Publikation: 2019

Ausgabe: 15

Nummer: 19

Seiten: 2211-2225

Art: Artikel

DOI: 10.2217/FON-2019-0180 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus